Platelet-mediated thrombosis and drug-eluting stents.
Publication
, Journal Article
Granada, JF; Price, MJ; French, PA; Steinhubl, SR; Cutlip, DE; Becker, RC; Smyth, SS; Dauerman, HL
Published in: Circ Cardiovasc Interv
December 1, 2011
Duke Scholars
Published In
Circ Cardiovasc Interv
DOI
EISSN
1941-7632
Publication Date
December 1, 2011
Volume
4
Issue
6
Start / End Page
629 / 637
Location
United States
Related Subject Headings
- Ticlopidine
- Thiophenes
- Risk Factors
- Purinergic P2Y Receptor Antagonists
- Prasugrel Hydrochloride
- Platelet Activation
- Piperazines
- Humans
- Equipment Design
- Drug-Eluting Stents
Citation
APA
Chicago
ICMJE
MLA
NLM
Granada, J. F., Price, M. J., French, P. A., Steinhubl, S. R., Cutlip, D. E., Becker, R. C., … Dauerman, H. L. (2011). Platelet-mediated thrombosis and drug-eluting stents. Circ Cardiovasc Interv, 4(6), 629–637. https://doi.org/10.1161/CIRCINTERVENTIONS.111.964635
Granada, Juan F., Matthew J. Price, Patricia A. French, Steven R. Steinhubl, Donald E. Cutlip, Richard C. Becker, Susan S. Smyth, and Harold L. Dauerman. “Platelet-mediated thrombosis and drug-eluting stents.” Circ Cardiovasc Interv 4, no. 6 (December 1, 2011): 629–37. https://doi.org/10.1161/CIRCINTERVENTIONS.111.964635.
Granada JF, Price MJ, French PA, Steinhubl SR, Cutlip DE, Becker RC, et al. Platelet-mediated thrombosis and drug-eluting stents. Circ Cardiovasc Interv. 2011 Dec 1;4(6):629–37.
Granada, Juan F., et al. “Platelet-mediated thrombosis and drug-eluting stents.” Circ Cardiovasc Interv, vol. 4, no. 6, Dec. 2011, pp. 629–37. Pubmed, doi:10.1161/CIRCINTERVENTIONS.111.964635.
Granada JF, Price MJ, French PA, Steinhubl SR, Cutlip DE, Becker RC, Smyth SS, Dauerman HL. Platelet-mediated thrombosis and drug-eluting stents. Circ Cardiovasc Interv. 2011 Dec 1;4(6):629–637.
Published In
Circ Cardiovasc Interv
DOI
EISSN
1941-7632
Publication Date
December 1, 2011
Volume
4
Issue
6
Start / End Page
629 / 637
Location
United States
Related Subject Headings
- Ticlopidine
- Thiophenes
- Risk Factors
- Purinergic P2Y Receptor Antagonists
- Prasugrel Hydrochloride
- Platelet Activation
- Piperazines
- Humans
- Equipment Design
- Drug-Eluting Stents